Physician profile
Thomas P Harder
NPI 1174568612
$24,449.12
in general payments reported to CMS, 2019-2025
44 companies · $4,856 in 2025
The $4,856 reported for 2025 was more than what 85% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,803 · 2020: $2,737 · 2021: $2,275 · 2022: $3,118 · 2023: $3,712 · 2024: $3,947 · 2025: $4,856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,353.19 |
| Education | $162.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,070.73 | 2019-2025 | |
| Amgen INC. | $4,025.28 | 2019-2025 | Enbrel, Evenity, Otezla |
| Astrazeneca Pharmaceuticals LP | $2,467.02 | 2021-2025 | Saphnelo |
| Ucb, INC. | $2,118.11 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $1,362.05 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,218.26 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,114.34 | 2019-2025 | Orencia |
| Janssen Biotech, INC. | $1,090.85 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $804.69 | 2019-2025 | Taltz |
| Radius Health, INC. | $699.89 | 2019-2025 | Tymlos |
| Glaxosmithkline, LLC. | $617.40 | 2019-2025 | Benlysta |
| Genentech USA, INC. | $527.79 | 2019-2025 | Actemra |
| Mallinckrodt Hospital Products INC. | $380.09 | 2020-2025 | Acthar |
| Horizon Therapeutics Plc | $373.28 | 2019-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $371.70 | 2021-2024 | Cyltezo, Ofev |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $362.64 | 2019-2024 | |
| Aurinia Pharma U.S., INC. | $354.09 | 2021-2025 | Lupkynis |
| Sobi, INC | $225.62 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $210.97 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $192.12 | 2022-2023 | Arcalyst |
| Ani Pharmaceuticals, INC. | $186.78 | 2022-2024 | Purified Cortrophin Gel |
| Collegium Pharmaceutical, INC. | $185.45 | 2020-2025 | Xtampza, Belbuca |
| Alexion Pharmaceuticals, INC. | $142.54 | 2019-2024 | Strensiq |
| Celgene Corporation | $140.56 | 2019 | |
| Organon LLC | $108.48 | 2023-2025 | Hadlima |
| Kyowa Kirin, INC. | $98.26 | 2022-2024 | Crysvita |
| Zimmer Biomet Holdings, INC. | $94.15 | 2024-2025 | Gel-One Cross-Linked Hyaluronate |
| Actelion Pharmaceuticals US, INC. | $89.44 | 2020-2025 | Opsumit, Uptravi |
| Invivyd INC | $80.32 | 2024-2025 | Pemgarda |
| Sandoz INC. | $78.25 | 2023-2025 | Hyrimoz, Jubbonti |
| Almatica Pharma LLC | $76.14 | 2024 | Teriparatide |
| Pacira Therapeutics, INC. | $75.63 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $72.36 | 2019-2023 | Mitigare |
| Novo Nordisk INC | $69.01 | 2023-2025 | Wegovy |
| Medexus Pharma, INC. | $64.23 | 2019 | |
| Depuy Synthes Sales INC. | $60.67 | 2019-2023 | Orthovisc, Monovisc |
| Kiniksa Pharmaceuticals International, Plc | $49.75 | 2024 | Arcalyst |
| Kowa Pharmaceuticals America, INC. | $46.08 | 2022-2023 | Seglentis |
| Ultragenyx Pharmaceutical INC. | $38.97 | 2021-2024 | Crysvita |
| Fresenius Kabi USA, LLC | $35.30 | 2023-2024 | Sodium Chloride, Idacio |
| Tonix Medicines, INC. | $26.26 | 2025 | Tonmya |
| Sanofi-Aventis U.S. LLC | $16.98 | 2019 | |
| Celltrion USA INC. | $14.56 | 2023 | Yuflyma |
| Sebela Pharmaceuticals INC. | $12.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Harder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.